ARS Pharmaceuticals 株価情報 (NASDAQ: SPRY)

最新ニュース ARS Pharmaceuticals (NASDAQ:SPRY) 株価情報

ARS Pharmaceuticals

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

ARS Pharmaceuticals Inc

News

Guidance

SEAT

Vivid Seats Sees FY25 Revenue Of $730M - $810M Vs. $801.599M Est.

TRMB

Trimble Announced The 2025 Version Of Its Tekla Powerfab Steel Fabrication Management System

Mega Matrix's FlexTV Launched Seven English Dramas From March 3 To 7, 2025, Spanning Genres Such As Rebirth, Romance, Suspense, And Revenge

Vivid Seats Posts Q4 Net Loss Of $4.4M, Down 115% From Net Income Of $28.5M In Q4 FY23

Clearwater will acquire Beacon for an aggregate purchase price of approximately $560m, 60% of which will be paid in cash, with the remainder to be paid in shares of Clearwater Class A common stock valued at approximately $30.05 per share. With ARR of approximately $44m at the end of 2024, this platform has scale and market acceptance as a leading risk and modeling platform.
The purchase price for the Bistro software is $125m, of which $10m will be paid in cash and the remainder will be paid in shares of Class A common stock, valued at $30.00 per share. This transaction represents the purchase of a platform developed by Blackstone. &nbsp;
 &nbsp;

CWAN

Clearwater Plans Two Strategic Acquisitions; Agrees To Acquire Beacon For  Aggregate Purchase Price Of $560M And Blackstone's Bistro For $125M

VIAV

VIAVI Solutions Introduced The Cx200 Infrastructure Field Tester, A Handheld Instrument To Simplify Technicians' Work And Minimize Total Cost Of Ownership (Tco) When Testing, Maintaining And Troubleshooting Mission-critical Radio Networks

Vivid Seats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEAT#NASDAQ">SEAT</a>) reported quarterly sales of $199.81 million which beat the analyst consensus estimate of $194.15 million by 2.92 percent. This is a 0.76 percent increase over sales of $198.30 million the same period last year.

Earnings

Earnings Beats

Vivid Seats Q4 Sales $199.81M Beat $194.15M Estimate

BTDR

Bitdeer Technologies Announced Its Unaudited Mining And Operations Updates For February 2025, With Self-mined Bitcoin Of 110 Bitcoins, Down From January 2025 Due To Less Days In February

Taiwan Semiconductor Mfg. Co. Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) has reportedly approached U.S. chip designers Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) and Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) to invest in a joint venture (JV).
What Happened: With the joint venture, TSMC aims to operate Intel Corp.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) factories, according to a report by Reuters.
The proposal suggests that the Taiwanese chipmaker would manage Intel&#8217;s foundry division, which customizes chips for clients, but would not own more than 50%, according to sources in the report.
TSMC has also approached Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) for this JV, the report added.
SEE ALSO:<a href="https://www.benzinga.com/markets/equities/25/03/44269513/elon-musk-says-tesla-will-double-us-production-in-2-years-after-trump-backs-ev-giant-amid-stock-slump"> Elon Musk Says Tesla Will Double US Production in 2 Years After Trump Backs EV Giant Amid Stock Slump</a>
The discussions are in early stages and follow a request from the Trump administration for TSMC to aid in revitalizing Intel, a key U.S. industrial entity. The plan details and TSMC&#8217;s outreach to potential partners are being reported for the first time.
Any agreement would require approval from the Trump administration, which opposes full foreign ownership of Intel or its foundry division
Subscribe to the <a href="https://bztechtrends.beehiiv.com/subscribe">Benzinga Tech Trends newsletter</a> to get all the latest tech developments delivered to your inbox.
Intel&#8217;s shares have plummeted over 56% in the past year, and the company reported a net loss of $18.8 billion in 2024. The foundry division&#8217;s assets were valued at $108 billion as of December 31, according to a company filing.
Why It Matters: The proposal from TSMC comes at a time when the company is experiencing significant growth, driven by a surge in demand for its chips used in artificial intelligence applications.
In the first two months of 2025, TSMC<a href="https://www.benzinga.com/25/03/44213860/tsmc-rides-ai-wave-sales-surge-39-in-the-first-two-months-of-2025-on-higher-demand"> reported</a> a 39.2% increase in revenue, highlighting the robust demand for its products.
This growth is part of a broader trend, as TSMC&#8217;s CEO, C. C. Wei, emphasised that their U.S. expansion is<a href="https://www.benzinga.com/25/03/44195821/taiwan-semiconductor-chief-says-us-expansion-driven-by-ai-and-smartphone-boom-warns-of-supply-shortage"> driven</a> by the booming AI and smartphone markets, not political pressure.
This expansion includes a $100 billion investment plan to meet the rising demand from U.S. customers.
Additionally, Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) has<a href="https://www.benzinga.com/media/25/03/44255195/meta-taps-taiwan-semiconductor-to-build-ai-chip-aims-to-cut-nvidia-dependence-by-2026"> partnered</a> with TSMC to produce its first in-house AI chip, aiming to reduce dependence on suppliers like Nvidia.
This move underscores the growing importance of TSMC in the AI chip market. Meanwhile, Broadcom&#8216;s CEO, Hock Tan, has<a href="https://www.benzinga.com/markets/25/03/44184829/broadcom-ceo-hock-tan-brushes-off-intel-acquisition-speculation-ma-no-im-too-busy"> dismissed</a> speculation about a potential merger with Intel.
Benzinga has reached out to TSMC, Nvidia, Intel, Broadcom and Qualcomm for comments. This story will be updated as and when they respond.
Check out more of Benzinga's Consumer Tech coverage by <a href="https://www.benzinga.com/topic/consumer-tech">following this link</a>.
Read Next:
<a href="https://www.benzinga.com/25/03/44268506/elon-musk-led-spacex-inks-agreements-with-indias-top-telecom-providers-expands-addressable-market-by-over-850-million-users">Elon Musk&#8217;s SpaceX Inks Agreements With India&#8217;s Top Telecom Providers For Starlink, Expanding Access To 850 Million Users</a>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Equities

Markets

Tech

AVGO

INTC

NVDA

QCOM

TSMC Proposes Joint Venture With Nvidia, AMD And Broadcom To Operate Intel's Factories: Report

Waterdrop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WDH#NYSE">WDH</a>) reported quarterly sales of $94.09 million which beat the analyst consensus estimate of $93.89 million by 0.21 percent. This is a 1.32 percent increase over sales of $92.87 million the same period last year.

Waterdrop Q4 Sales $94.09M Beat $93.89M Estimate

Mizuho analyst Sean Kennedy initiates coverage on Moodys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCO#NYSE">MCO</a>) with a Neutral rating and announces Price Target of $504.

Price Target

Initiation

Analyst Ratings

Mizuho Initiates Coverage On Moodys with Neutral Rating, Announces Price Target of $504

Anatoly Dritschilo, Chairman of the Company's Board of Directors, will continue in his role as Co-CEO overseeing the Company's scientific and clinical trial activities.

Management

SHPH

Shuttle Pharmaceuticals Appoints Christopher Cooper As Interim Co-CEO

Contracts

NIPG

NIP Group Officially Renewed Their Partnership With Iconic Energy Drink Brand Red Bull

APPN

PEGA

Appian Announced That The Supreme Court Of Virginia Agreed To Hear Its Petition Seeking To Reinstate The $2.036B Judgement Against Pegasystems, Inc.

Mizuho analyst Sean Kennedy initiates coverage on S&amp;P Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) with a Outperform rating and announces Price Target of $599.

SPGI

Mizuho Initiates Coverage On S&P Global with Outperform Rating, Announces Price Target of $599

The funds will be used to maintain the company's velocity through its fully implanted Acclaim cochlear implant pivotal clinical trial and support other operations.
The $10 million lending facility has a five-year term, is unsecured, does not have a conversion feature, and defers interest for the first two years.&nbsp; &nbsp;

Envoy Medical, Inc. - Class A Common Stock

COCH

Envoy Medical Secures $10M In Financing From Its Largest Existing Shareholder, Billionaire Entrepreneur Glen Taylor

BURU

Nuburu On Tuesday Said Believes That The Intellectual Property, Key Personnel, Relationships It Retains Will Be Sufficient To Allow It To Continue To Develop And Operate Within The Laser Technology Field, Focused Attention On Applications In Defense, Semiconductor, Industrial Manufacturing Sectors

Centene Expects To Reaffirm Its Previously Issued 2025 Adjusted EPS Guidance Of Greater Than $7.25 (Est $7.23) - Filing

Target Announced The Return Of Target Circle Week March 23-29, Delivering Seven Days Of Exclusive Deals And Up To 40% Off For Members Of The Retailer's Free-to-join Target Circle Program

Nokia Announced That Canal+ Telecom, Will Deploy Its Lightspan And Altiplano Solution To Support The Transformation Of Its Fiber Network Across French Guiana And Guadeloupe

Health Care

Press Releases

ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

General

ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

Legal

ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S

ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy® (epinephrine nasal spray)

ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools

ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference

ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting

ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences

ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

Comments

ARS Pharmaceuticals

ニュース

最新ニュース ARS Pharmaceuticals (NASDAQ:SPRY) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル